O	0	13	Investigating	Investigate	VBG	B-VP
O	14	17	the	the	DT	B-NP
O	18	24	causes	cause	NNS	I-NP
O	25	27	of	of	IN	B-PP
O	28	31	low	low	JJ	B-NP
O	32	37	birth	birth	NN	I-NP
O	38	44	weight	weight	NN	I-NP
O	45	47	in	in	IN	B-PP
O	48	59	contrasting	contrast	VBG	B-VP
O	60	65	ovine	ovine	JJ	B-NP
O	66	75	paradigms	paradigm	NNS	I-NP
O	75	76	.	.	.	O

O	77	89	Intrauterine	Intrauterine	JJ	B-NP
O	90	96	growth	growth	NN	I-NP
O	97	108	restriction	restriction	NN	I-NP
O	109	110	(	(	(	O
O	110	114	IUGR	IUGR	NN	B-NP
O	114	115	)	)	)	O
O	116	121	still	still	RB	B-ADVP
O	122	130	accounts	account	VBZ	B-VP
O	131	134	for	for	IN	B-PP
O	135	136	a	a	DT	B-NP
O	137	142	large	large	JJ	I-NP
O	143	152	incidence	incidence	NN	I-NP
O	153	155	of	of	IN	B-PP
O	156	162	infant	infant	NN	B-NP
O	163	172	mortality	mortality	NN	I-NP
O	173	176	and	and	CC	I-NP
O	177	186	morbidity	morbidity	NN	I-NP
O	187	196	worldwide	worldwide	RB	B-ADVP
O	196	197	.	.	.	O

O	198	202	Many	Many	JJ	B-NP
O	203	205	of	of	IN	B-PP
O	206	209	the	the	DT	B-NP
O	210	221	circulatory	circulatory	JJ	I-NP
O	222	225	and	and	CC	I-NP
O	226	235	transport	transport	NN	I-NP
O	236	246	properties	property	NNS	I-NP
O	247	249	of	of	IN	B-PP
O	250	253	the	the	DT	B-NP
O	254	259	sheep	sheep	NN	I-NP
B-Organ	260	268	placenta	placenta	NN	I-NP
O	269	272	are	be	VBP	B-VP
O	273	280	similar	similar	JJ	B-ADJP
O	281	283	to	to	TO	B-PP
O	284	289	those	those	DT	B-NP
O	290	292	of	of	IN	B-PP
O	293	296	the	the	DT	B-NP
O	297	302	human	human	JJ	I-NP
B-Organ	303	311	placenta	placenta	NN	I-NP
O	312	315	and	and	CC	B-PP
O	316	318	as	as	IN	B-PP
O	319	323	such	such	JJ	B-NP
O	323	324	,	,	,	O
O	325	328	the	the	DT	B-NP
O	329	337	pregnant	pregnant	JJ	I-NP
O	338	343	sheep	sheep	NN	I-NP
O	344	350	offers	offer	VBZ	B-VP
O	351	353	an	an	DT	B-NP
O	354	363	excellent	excellent	JJ	I-NP
O	364	369	model	model	NN	I-NP
O	370	372	in	in	IN	B-PP
O	373	378	which	which	WDT	B-NP
O	379	381	to	to	TO	B-VP
O	382	387	study	study	VB	I-VP
O	388	391	the	the	DT	B-NP
O	392	403	development	development	NN	I-NP
O	404	406	of	of	IN	B-PP
O	407	411	IUGR	IUGR	NN	B-NP
O	411	412	.	.	.	O

O	413	416	Two	Two	CD	B-NP
O	417	424	natural	natural	JJ	I-NP
O	425	431	models	model	NNS	I-NP
O	432	434	of	of	IN	B-PP
O	435	440	ovine	ovine	JJ	B-NP
O	441	445	IUGR	IUGR	NN	I-NP
O	446	449	are	be	VBP	B-VP
O	450	455	those	those	DT	B-NP
O	456	458	of	of	IN	B-PP
O	459	471	hyperthermic	hyperthermic	JJ	B-NP
O	472	480	exposure	exposure	NN	I-NP
O	481	487	during	during	IN	B-PP
O	488	497	pregnancy	pregnancy	NN	B-NP
O	497	498	,	,	,	O
O	499	502	and	and	CC	O
O	503	513	adolescent	adolescent	JJ	B-NP
O	514	525	overfeeding	overfeeding	NN	I-NP
O	525	526	,	,	,	O
O	527	531	also	also	RB	B-ADVP
O	532	538	during	during	IN	B-PP
O	539	548	pregnancy	pregnancy	NN	B-NP
O	548	549	.	.	.	O

O	550	554	Both	Both	DT	B-NP
O	555	561	models	model	NNS	I-NP
O	562	567	yield	yield	VBP	B-VP
O	568	581	significantly	significantly	RB	B-NP
O	582	589	reduced	reduce	VBN	I-NP
B-Organ	590	599	placental	placental	JJ	I-NP
O	600	607	weights	weight	NNS	I-NP
O	608	611	and	and	CC	O
O	612	614	an	an	DT	B-NP
O	615	629	asymmetrically	asymmetrically	RB	I-NP
O	630	636	growth	growth	NN	I-NP
O	636	637	-	-	HYPH	O
O	637	647	restricted	restrict	VBN	B-NP
B-Developing_anatomical_structure	648	653	fetus	fetus	NN	I-NP
O	653	654	,	,	,	O
O	655	658	and	and	CC	O
O	659	666	display	display	VBP	B-VP
O	667	674	altered	alter	VBN	I-VP
O	675	683	maternal	maternal	JJ	B-NP
O	684	691	hormone	hormone	NN	I-NP
O	692	706	concentrations	concentration	NNS	I-NP
O	706	707	,	,	,	O
O	708	718	indicative	indicative	JJ	B-ADJP
O	719	721	of	of	IN	B-PP
O	722	724	an	an	DT	B-NP
O	725	733	impaired	impaired	JJ	I-NP
B-Cell	734	745	trophoblast	trophoblast	NN	I-NP
O	746	754	capacity	capacity	NN	I-NP
O	754	755	.	.	.	O

O	756	768	Additionally	Additionally	RB	B-ADVP
O	768	769	,	,	,	O
O	770	778	impaired	impaired	JJ	B-NP
B-Organ	779	788	placental	placental	JJ	I-NP
O	789	801	angiogenesis	angiogenesis	NN	I-NP
O	802	805	and	and	CC	O
B-Organism_substance	806	820	uteroplacental	uteroplacental	JJ	B-NP
I-Organism_substance	821	826	blood	blood	NN	I-NP
O	827	831	flow	flow	NN	I-NP
O	832	839	appears	appear	VBZ	B-VP
O	840	842	to	to	TO	I-VP
O	843	845	be	be	VB	I-VP
O	846	848	an	an	DT	B-NP
O	849	854	early	early	JJ	I-NP
O	855	861	defect	defect	NN	I-NP
O	862	864	in	in	IN	B-PP
O	865	869	both	both	CC	B-NP
O	870	873	the	the	DT	I-NP
O	874	886	hyperthermic	hyperthermic	JJ	I-NP
O	887	890	and	and	CC	I-NP
O	891	901	adolescent	adolescent	JJ	I-NP
O	902	911	paradigms	paradigm	NNS	I-NP
O	911	912	.	.	.	O

O	913	916	The	The	DT	B-NP
O	917	924	effects	effect	NNS	I-NP
O	925	927	of	of	IN	B-PP
O	928	933	these	these	DT	B-NP
O	934	945	alterations	alteration	NNS	I-NP
O	946	948	in	in	IN	B-PP
B-Organ	949	958	placental	placental	JJ	B-NP
O	959	969	functional	functional	JJ	I-NP
O	970	981	development	development	NN	I-NP
O	982	988	appear	appear	VBP	B-VP
O	989	991	to	to	TO	I-VP
O	992	994	be	be	VB	I-VP
O	995	1007	irreversible	irreversible	JJ	B-ADJP
O	1007	1008	.	.	.	O

O	1009	1013	IUGR	IUGR	NN	B-NP
B-Developing_anatomical_structure	1014	1021	fetuses	fetus	NNS	I-NP
O	1022	1025	are	be	VBP	B-VP
O	1026	1030	both	both	DT	B-ADJP
O	1031	1038	hypoxic	hypoxic	JJ	I-ADJP
O	1039	1042	and	and	CC	I-ADJP
O	1043	1056	hypoglycaemic	hypoglycaemic	JJ	I-ADJP
O	1056	1057	,	,	,	O
O	1058	1061	and	and	CC	O
O	1062	1066	have	have	VBP	B-VP
O	1067	1074	reduced	reduce	VBN	I-VP
O	1075	1082	insulin	insulin	NN	B-NP
O	1083	1086	and	and	CC	I-NP
O	1087	1094	insulin	insulin	NN	I-NP
O	1094	1095	-	-	HYPH	B-NP
O	1095	1099	like	like	JJ	I-NP
O	1100	1106	growth	growth	NN	I-NP
O	1107	1113	factor	factor	NN	I-NP
O	1113	1114	-	-	HYPH	B-NP
O	1114	1115	1	1	CD	I-NP
O	1116	1117	(	(	(	O
O	1117	1120	IGF	IGF	NN	B-NP
O	1120	1121	-	-	HYPH	B-NP
O	1121	1122	1	1	CD	I-NP
O	1122	1123	)	)	)	O
O	1123	1124	,	,	,	O
O	1125	1128	and	and	CC	O
O	1129	1137	elevated	elevate	VBN	B-VP
O	1138	1152	concentrations	concentration	NNS	B-NP
O	1153	1155	of	of	IN	B-PP
O	1156	1163	lactate	lactate	NN	B-NP
O	1163	1164	.	.	.	O

O	1165	1172	However	However	RB	B-ADVP
O	1172	1173	,	,	,	O
B-Developing_anatomical_structure	1174	1179	fetal	fetal	JJ	B-NP
O	1180	1191	utilization	utilization	NN	I-NP
O	1192	1194	of	of	IN	B-PP
O	1195	1201	oxygen	oxygen	NN	B-NP
O	1202	1205	and	and	CC	I-NP
O	1206	1213	glucose	glucose	NN	I-NP
O	1213	1214	,	,	,	O
O	1215	1217	on	on	IN	B-PP
O	1218	1219	a	a	DT	B-NP
O	1220	1226	weight	weight	NN	I-NP
O	1227	1232	basis	basis	NN	I-NP
O	1232	1233	,	,	,	O
O	1234	1240	remain	remain	VBP	B-VP
O	1241	1249	constant	constant	JJ	B-ADJP
O	1250	1258	compared	compare	VBN	B-PP
O	1259	1263	with	with	IN	B-PP
O	1264	1271	control	control	NN	B-NP
O	1272	1283	pregnancies	pregnancy	NNS	I-NP
O	1283	1284	.	.	.	O

O	1285	1295	Maintained	Maintain	VBN	B-NP
O	1296	1307	utilization	utilization	NN	I-NP
O	1308	1310	of	of	IN	B-PP
O	1311	1316	these	these	DT	B-NP
O	1317	1327	substrates	substrate	NNS	I-NP
O	1327	1328	,	,	,	O
O	1329	1331	in	in	IN	B-PP
O	1332	1333	a	a	DT	B-NP
O	1334	1343	substrate	substrate	NN	I-NP
O	1343	1344	-	-	HYPH	B-NP
O	1344	1353	deficient	deficient	JJ	I-NP
O	1354	1365	environment	environment	NN	I-NP
O	1365	1366	,	,	,	O
O	1367	1375	suggests	suggest	VBZ	B-VP
O	1376	1385	increased	increase	VBN	B-NP
O	1386	1399	sensitivities	sensitivity	NNS	I-NP
O	1400	1402	to	to	TO	B-PP
O	1403	1412	metabolic	metabolic	JJ	B-NP
O	1413	1420	signals	signal	NNS	I-NP
O	1420	1421	,	,	,	O
O	1422	1427	which	which	WDT	B-NP
O	1428	1431	may	may	MD	B-VP
O	1432	1436	play	play	VB	I-VP
O	1437	1438	a	a	DT	B-NP
O	1439	1443	role	role	NN	I-NP
O	1444	1446	in	in	IN	B-PP
O	1447	1450	the	the	DT	B-NP
O	1451	1462	development	development	NN	I-NP
O	1463	1465	of	of	IN	B-PP
O	1466	1475	metabolic	metabolic	JJ	B-NP
O	1476	1484	diseases	disease	NNS	I-NP
O	1485	1487	in	in	IN	B-PP
O	1488	1493	later	later	JJ	B-NP
O	1494	1499	adult	adult	JJ	I-NP
O	1500	1504	life	life	NN	I-NP
O	1504	1505	.	.	.	O

